

No effect of vitamin D supplementation on circulating concentrations of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinases-1 (TIMP-1) in adults aged 20–40 and ≥64 years

A. Lucey¹, T. Hill¹, S. Muldowney¹, K. Seamans¹, J. M. W. Wallace³, G Horigan³, M. S. Barnes³, K. D. Cashman^{1,2} and M. Kiely¹

¹Department of Food & Nutritional Sciences and ²Department of Medicine, University College Cork, Cork, Republic of Ireland and ³Northern Ireland Centre for Food and Health, University of Ulster, Coleraine BT52 1SA, UK

Tissue matrix metalloproteinases participate in extracellular matrix remodelling and degradation. Increased expression of MMP-9 and its inhibitor TIMP-1 are linked to unfavourable cardiovascular conditions, including inflammatory damage leading to increased plaque instability⁽¹⁾. Vitamin D insufficiency is associated with higher MMP-9 concentrations, while vitamin D supplementation has been shown to decrease circulating MMP-9 and TIMP-1 concentrations in vitamin D-deficient adults⁽²⁾.

The effect of vitamin D supplementation (0, 5, 10 and 15 µg cholecalciferol/d) on MMP-9 and TIMP-1 concentrations was investigated in two randomised placebo-controlled double-blind 22-week intervention studies in men and women aged 20–40 years (*n* 215; during winter 2006–7⁽³⁾) and ≥64 years (*n* 215; during winter 2007–8⁽⁴⁾) from Cork and Coleraine. Fasting serum levels of MMP-9, TIMP-1 and 25-hydroxyvitamin D (25(OH)D) were measured by ELISA at baseline and end point.

	Treatment group (µg cholecalciferol/d)																<i>P</i>
	Placebo				5				10				15				
	BL		EP		BL		EP		BL		EP		BL		EP		
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	
20–40 years	(n 56)				(n 50)				(n 57)				(n 52)				
MMP-9 (ng/ml)	237	175	187	147	222	177	183	150	242	200	197	166	238	17	210	185	0.381
TIMP-1 (ng/ml)	158	34	156	38	167	37	159	41	161	39	152	37	171	39	155	39	0.441
25(OH) D (nmol/l)	76.8	33	41.8 ^a	18	71.3	27	53.4 ^b	15	77.6	33	62.1 ^c	22	79.7	30	72.4 ^d	21	<0.001 ⁽³⁾
≥64 years	(n 56)				(n 51)				(n 57)				(n 51)				
MMP-9 (ng/ml)	205	189	251	233	188	192	211	203	197	206	196	187	180	172	229	228	0.603
TIMP-1 (ng/ml)	178	42	186	43	186	49	188	54	182	48	175	42	187	37	185	41	0.815
25(OH) D (nmol/l)	58.9	23	43.1 ^a	17	57.9	23	58 ^b	16	59.2	26	70.6 ^c	18	53.73	18	76.2 ^c	21	<0.001 ⁽⁴⁾

BL, baseline; EP, end point (EP). Means in a row with unlike superscript letters were significantly different (*P*<0.001).

ANOVA showed no baseline differences in the circulating concentrations of MMP-9, TIMP-1 or 25(OH)D between the four treatment groups. Baseline MMP-9 and TIMP-1 concentrations were significantly higher in adults aged 20–40 years (*P*<0.001) and adults aged ≥64 years (*P*<0.01) in Coleraine than in Cork. Linear regression analysis showed study centre to be the main predictor of MMP-9 (adjusted *R*² 0.474; *P*<0.001) and TIMP-1 (adjusted *R*² 0.326; *P*<0.001) concentrations in adults aged 20–40 years. In both age-groups pre- and post-intervention 25(OH)D concentrations were not associated with levels of MMP-9, TIMP-1 or MMP-9:TIMP-1. In both age-groups repeated measures analysis revealed no significant effect of the intervention on MMP-9 and TIMP-1 concentrations across the four groups, adjusting for centre, age, gender and BMI.

In conclusion, vitamin D supplementation had no effect on circulating MMP-9 and TIMP-1 concentrations in apparently-healthy adults aged 20–40 and ≥64 years.

We wish to acknowledge the UK Food Standards Agency and the Irish Department of Agriculture, Food & Fisheries through the Food Institutional Research Measure for their support.

- Janssens S & Lijnen HR (2006) *Cardiovasc Res* **69**, 585–594.
- Timms PM, Mannan N, Hitman GA *et al.* (2002) *Q J Med* **95**, 787–796.
- Cashman KD, Hill TR, Lucey AJ *et al.* (2008) *Am J Clin Nutr* **88**, 1535–1542.
- Cashman KD, Wallace JMW, Horigan G *et al.* (2009) *Am J Clin Nutr* **89**, 1–9.